Atyr Pharma Inc (ATYR)

$0.96 -0.01 (-1.03%)
Market Cap 86.50M
Revenue (ttm) 240,000.00
Net Income (ttm) -64.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -26,675.00%
Debt to Equity Ratio 0.00
Volume 3,572,300
Avg Vol 2,309,460
Day's Range N/A - N/A
Shares Out 97.99M
Stochastic %K 78%
Beta 0.60
Analysts Sell
Price Target $4.00

Company Profile

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitiv...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 731 8389
Fax: 858 731 8394
Address:
10240 Sorrento Valley Road, Suite 300, San Diego, United States
trader2sde
trader2sde Feb. 3 at 10:05 PM
$ATYR
1 · Reply
trader2sde
trader2sde Feb. 3 at 9:50 PM
$ATYR
0 · Reply
trader2sde
trader2sde Feb. 3 at 9:49 PM
$ATYR we think the FDA will agree on the drug but the question of cost will be a topic of discussion. so be it. a middle ground will found (net cost for medicare or any part gvt has to cover). price discussion with private insurances is separate topic. now ps being an orphan disease its cost will not have a major impact on federal costs. there is serious demande for ps drug also worldwide with Europe and Japan being a huge market.
0 · Reply
ClearCities
ClearCities Feb. 3 at 9:12 PM
$ATYR What are the odds this goes bck to 7?
0 · Reply
vanguard100
vanguard100 Feb. 3 at 8:28 PM
$ATYR still have this on the radar 📡...Can really pop imo.....Keenly watching...
0 · Reply
cliffman1983
cliffman1983 Feb. 3 at 8:27 PM
$ATYR I'll be back
1 · Reply
BobbyBalentino
BobbyBalentino Feb. 3 at 8:17 PM
$ATYR This honestly held super well with market tanking
0 · Reply
RocketLabs
RocketLabs Feb. 3 at 7:47 PM
$ATYR keep in mind that the FDA doesn't necessarily need to agree to "discuss a way forward". They could have declined if they didn't see one.
2 · Reply
__Godzilla__
__Godzilla__ Feb. 3 at 7:12 PM
$ATYR Perhaps the market is disappointed that the the FDA meeting is happening in April instead of Q1 as was previously planned.
1 · Reply
Ucke77
Ucke77 Feb. 3 at 5:56 PM
$ATYR Back to normal, back into the red, it's just infuriating 🤮
1 · Reply
Latest News on ATYR
The IPO Market Faces a Busy Week. These Stocks Are Making Their Debuts.

Feb 3, 2026, 2:46 PM EST - 9 hours ago

The IPO Market Faces a Busy Week. These Stocks Are Making Their Debuts.

FPS LFTO LIFE YSS

aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis

Feb 3, 2026, 8:00 AM EST - 15 hours ago

aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis

U.S. IPO Weekly Recap: Trio Of Sizable Listings Underwhelm To Close Out January

Jan 30, 2026, 10:25 PM EST - 4 days ago

U.S. IPO Weekly Recap: Trio Of Sizable Listings Underwhelm To Close Out January

AGMB BOBS EIKN FPS LFTO LIFE OFRM

Ethos Technologies: A Surprisingly Soft Debut

Jan 30, 2026, 12:21 AM EST - 4 days ago

Ethos Technologies: A Surprisingly Soft Debut

LIFE

Insurance platform Ethos Technologies valued at $1.2 billion in Nasdaq debut

Jan 29, 2026, 12:30 PM EST - 5 days ago

Insurance platform Ethos Technologies valued at $1.2 billion in Nasdaq debut

LIFE

Ethos Announces Pricing of Initial Public Offering

Jan 28, 2026, 10:38 PM EST - 6 days ago

Ethos Announces Pricing of Initial Public Offering

LIFE

Ethos Technologies prices US IPO at $19/share, Bloomberg News reports

Jan 28, 2026, 9:05 PM EST - 6 days ago

Ethos Technologies prices US IPO at $19/share, Bloomberg News reports

LIFE

U.S. IPO Weekly Recap: Equipment Rental Rises While Crypto Company Crashes In 2-IPO Week

Jan 23, 2026, 10:45 PM EST - 11 days ago

U.S. IPO Weekly Recap: Equipment Rental Rises While Crypto Company Crashes In 2-IPO Week

BTGO CSIG EQPT LIFE PICS PPHC YSS

Ethos and North American Collaborate to Offer Accumulation Indexed Universal Life Product

Jan 7, 2026, 8:01 AM EST - 27 days ago

Ethos and North American Collaborate to Offer Accumulation Indexed Universal Life Product

LIFE

U.S. IPO Weekly Recap: Small Issuers And SPACs Join The Pipeline In Short Holiday Week

Jan 2, 2026, 10:35 PM EST - 4 weeks ago

U.S. IPO Weekly Recap: Small Issuers And SPACs Join The Pipeline In Short Holiday Week

APC BTGO EQPT GRAY IBL KLK LIFE

Ethos and Aflac Partner to Bring Supplemental Health Product Suite to Independent Distribution

Dec 18, 2025, 8:01 AM EST - 6 weeks ago

Ethos and Aflac Partner to Bring Supplemental Health Product Suite to Independent Distribution

LIFE

Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders

Dec 15, 2025, 2:45 PM EST - 7 weeks ago

Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders

aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR

Dec 8, 2025, 3:25 AM EST - 2 months ago

aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR

ATYR DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Dec 7, 2025, 9:02 AM EST - 2 months ago

ATYR DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure

Dec 6, 2025, 12:58 PM EST - 2 months ago

ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Dec 4, 2025, 10:56 AM EST - 2 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 8, 2025 in aTyr Lawsuit – ATYR

Dec 3, 2025, 4:21 PM EST - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 8, 2025 in aTyr Lawsuit – ATYR

ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Dec 3, 2025, 9:22 AM EST - 2 months ago

ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Dec 1, 2025, 6:32 PM EST - 2 months ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

The Short List — Top 10 Most Shorted Stocks Right Now

Nov 26, 2025, 11:34 AM EST - 2 months ago

The Short List — Top 10 Most Shorted Stocks Right Now

CMBM HIMS HTZ LCID NTLA REPL SOC

aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves Forward -- Hagens Berman

Nov 25, 2025, 4:08 PM EST - 2 months ago

aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves Forward -- Hagens Berman

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 8, 2025 in aTyr Pharma, Inc. Lawsuit - ATYR

Nov 20, 2025, 8:45 AM EST - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 8, 2025 in aTyr Pharma, Inc. Lawsuit - ATYR

ATYR INVESTOR NOTICE: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged -- Hagens Berman

Nov 18, 2025, 2:03 PM EST - 2 months ago

ATYR INVESTOR NOTICE: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged -- Hagens Berman

aTyr Pharma, Inc. (ATYR) Failed Drug Trial Spurs Securities Lawsuit; Class Period Significantly Enlarged -- Hagens Berman

Nov 11, 2025, 9:23 AM EST - 3 months ago

aTyr Pharma, Inc. (ATYR) Failed Drug Trial Spurs Securities Lawsuit; Class Period Significantly Enlarged -- Hagens Berman

aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 10, 2025, 8:00 AM EST - 3 months ago

aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference

aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update

Nov 6, 2025, 4:01 PM EST - 3 months ago

aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update

ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ATyr Pharma

Nov 4, 2025, 11:49 AM EST - 3 months ago

ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ATyr Pharma

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Oct 30, 2025, 11:33 AM EDT - 3 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 8, 2025 in aTyr Lawsuit - ATYR

Oct 30, 2025, 8:45 AM EDT - 3 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 8, 2025 in aTyr Lawsuit - ATYR

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Oct 28, 2025, 9:34 AM EDT - 3 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

ATYR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Oct 23, 2025, 1:28 PM EDT - 3 months ago

ATYR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

trader2sde
trader2sde Feb. 3 at 10:05 PM
$ATYR
1 · Reply
trader2sde
trader2sde Feb. 3 at 9:50 PM
$ATYR
0 · Reply
trader2sde
trader2sde Feb. 3 at 9:49 PM
$ATYR we think the FDA will agree on the drug but the question of cost will be a topic of discussion. so be it. a middle ground will found (net cost for medicare or any part gvt has to cover). price discussion with private insurances is separate topic. now ps being an orphan disease its cost will not have a major impact on federal costs. there is serious demande for ps drug also worldwide with Europe and Japan being a huge market.
0 · Reply
ClearCities
ClearCities Feb. 3 at 9:12 PM
$ATYR What are the odds this goes bck to 7?
0 · Reply
vanguard100
vanguard100 Feb. 3 at 8:28 PM
$ATYR still have this on the radar 📡...Can really pop imo.....Keenly watching...
0 · Reply
cliffman1983
cliffman1983 Feb. 3 at 8:27 PM
$ATYR I'll be back
1 · Reply
BobbyBalentino
BobbyBalentino Feb. 3 at 8:17 PM
$ATYR This honestly held super well with market tanking
0 · Reply
RocketLabs
RocketLabs Feb. 3 at 7:47 PM
$ATYR keep in mind that the FDA doesn't necessarily need to agree to "discuss a way forward". They could have declined if they didn't see one.
2 · Reply
__Godzilla__
__Godzilla__ Feb. 3 at 7:12 PM
$ATYR Perhaps the market is disappointed that the the FDA meeting is happening in April instead of Q1 as was previously planned.
1 · Reply
Ucke77
Ucke77 Feb. 3 at 5:56 PM
$ATYR Back to normal, back into the red, it's just infuriating 🤮
1 · Reply
__Godzilla__
__Godzilla__ Feb. 3 at 4:32 PM
$ATYR Buy the rumor, sell the news.
1 · Reply
OnlyBuyMoreShareSqueezes
OnlyBuyMoreShareSqueezes Feb. 3 at 4:12 PM
$ATYR HOLD LONG ! let’s make a break and hold 1 . To be safe let’s consolidate $1.7-2 and leg up higher , fda guidance this year in Jan is specifically designed for our type of drug , this is bullish for our stock . We will go back to 6 long term
1 · Reply
trader2sde
trader2sde Feb. 3 at 1:28 PM
$ATYR now expect evidently the reactions of HC WAINWRIGHT, CANTOR and others ...probably views with 2 outcomes as last time. but this is positive having a new meeting with the FDA. ( remember there is no drug for lung sarcoidosis).
0 · Reply
trader2sde
trader2sde Feb. 3 at 1:23 PM
$ATYR https://www.stocktitan.net/news/ATYR/a-tyr-pharma-announces-scheduling-of-fda-type-c-meeting-to-discuss-yx144up3xwvc.html
0 · Reply
trader2sde
trader2sde Feb. 3 at 1:20 PM
$ATYR
0 · Reply
A416
A416 Feb. 3 at 1:18 PM
$ATYR Today we announced that we are scheduled to meet with the U.S. FDA in mid-April 2026 for a Type C meeting to review the results from the Phase 3 EFZO-FIT™ study and determine the path forward for #efzofitimod in #pulmonarysarcoidosis. Read more: http://bit.ly/4bEnIxr
0 · Reply
rio245
rio245 Feb. 3 at 1:12 PM
$ATYR
0 · Reply
NNTrader
NNTrader Feb. 3 at 7:35 AM
$ATYR any news why it's up?
1 · Reply
trader2sde
trader2sde Feb. 2 at 9:22 PM
$ATYR we stand in the $4 target range but still substantial.
1 · Reply
Cris0
Cris0 Feb. 2 at 8:39 PM
$ATYR 5 soon
1 · Reply
cliffman1983
cliffman1983 Feb. 2 at 8:11 PM
$ATYR Give me 1$$$ 💸
1 · Reply
WelshDragon75
WelshDragon75 Feb. 2 at 8:01 PM
$ATYR over the $1 let’s go!
0 · Reply